CVT: FDA Continues to Review Ranexa Applications

CV Therapeutics, Inc. announced that it has been informed by the U.S. Food and Drug Administration (FDA) that it is continuing its review of CV Therapeutics’ pending applications for Ranexa (ranolazine extended-release tablets) past the Prescription Drug User Fee Act (PDUFA) action date of July 27, 2008.
The Earth Times